WO2008081255A1 - Derivatives of acid polysaccharides - Google Patents

Derivatives of acid polysaccharides Download PDF

Info

Publication number
WO2008081255A1
WO2008081255A1 PCT/IB2007/003973 IB2007003973W WO2008081255A1 WO 2008081255 A1 WO2008081255 A1 WO 2008081255A1 IB 2007003973 W IB2007003973 W IB 2007003973W WO 2008081255 A1 WO2008081255 A1 WO 2008081255A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
polysaccharides
autocrosslinked
polysaccharide
mmols
Prior art date
Application number
PCT/IB2007/003973
Other languages
French (fr)
Inventor
Luca Stucchi
Marco Bosco
Rita Gianni
Fabrizio Picotti
Original Assignee
Sigea S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigea S.R.L. filed Critical Sigea S.R.L.
Priority to JP2009543534A priority Critical patent/JP5372773B2/en
Priority to CA2673947A priority patent/CA2673947C/en
Priority to EP07859095.7A priority patent/EP2097457B1/en
Priority to PL07859095T priority patent/PL2097457T3/en
Priority to AU2007341078A priority patent/AU2007341078B2/en
Priority to ES07859095.7T priority patent/ES2633712T3/en
Priority to US12/521,307 priority patent/US8247546B2/en
Publication of WO2008081255A1 publication Critical patent/WO2008081255A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00Preparation of cellulose ethers
    • C08B11/02Alkyl or cycloalkyl ethers
    • C08B11/04Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/10Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
    • C08B11/12Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/005Crosslinking of cellulose derivatives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0033Xanthan, i.e. D-glucose, D-mannose and D-glucuronic acid units, saubstituted with acetate and pyruvate, with a main chain of (beta-1,4)-D-glucose units; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Definitions

  • This invention relates to acid autocrosslinked polysaccharides characterised by the concomitant presence of esters with non-polysaccharide carboxylic acids and esters between the acid groups of the same polysaccharide and the alcoholic groups of the repetitive units.
  • carboxylated polysaccharides constitute raw materials of considerable interest for a wide variety of applications in the pharmaceutical and cosmetic industries.
  • Some of them, such as hyaluronic acid (HA) are particularly valued for their high level of biotolerability and hydratability.
  • HA hyaluronic acid
  • the choice of material is often connected with cost aspects based on the value and importance of the final application.
  • EP 0941253 describes the synthesis of HA derivatives with butyric anhydride in a basic environment, to obtain a product not crosslinked, having esterified hydroxy groups and which does not undergo any significant modification of its viscoelastic properties in aqueous solution.
  • the process involves the use of the quaternary ammonium salt of HA and dimethylformamide (DMF) as aprotic solvent.
  • DMF dimethylformamide
  • EP 341745 teaches that autocrosslinking is obtained by "activating" the carboxyl by substituting the -OH group with an electron-attractor group X that allows the carbonyl carbon to be attached by a nucleophil (such as the -OH group of the monosaccharide units), with simultaneous detachment of X.
  • the reagents described which are able to activate the carboxyl are the typical, well-known reagents that supply activated esters in peptide synthesis, such as water-soluble carbodiimides, carbonyldiimidazole, carbonyltriazole, N-hydroxysuccinimide, p-nitrophenol, p-nitrophenyltrifluoracetate, and salts of 2-halogen-N-alkylpyridine [T. Mukaiyama, Ang. Chem., 10 (18) 1979, 707-808]; the reaction is catalysed with triethylamine (TEA).
  • TAA triethylamine
  • the starting carboxylated polysaccharides are salified as tetrabutylammonium (TBA) salts soluble in aprotic solvents, such as dimethyl sulphoxide (DMSO), to obtain a single reaction phase.
  • TAA tetrabutylammonium
  • aprotic solvents such as dimethyl sulphoxide (DMSO)
  • DMSO dimethyl sulphoxide
  • the same patent also claims the use of sodium salts in the same aprotic organic solvents to conduct the same reaction.
  • this salt is not soluble in solvents such as DMF or DMSO.
  • the invention relates to natural or semisynthetic derivatives of acid polysaccharides wherein the alcoholic groups of the repetitive units occur, more or less extensively, in the form of esters with non-polysaccharide carboxylic acids, and the uronic acid groups are esterified, to a different extent, with other free alcoholic groups present in the polysaccharide chains.
  • This latter type of bond induces autocrosslinking of the polysaccharide, thus influencing the viscoelastic behaviour of the end products;
  • a suitable choice of acyl residue used to esterify the alcoholic hydroxyls enables other chemico-physical properties, such as hydrophilia/lipophilia and viscosity, to be modulated.
  • the degree of autocrosslinking which is adjustable and reproducible, influences the characteristics of the final products (rigid gels, weak gels, products with increased viscosity).
  • the derivatives according to the invention can be used as constituents of medical devices of various grades (I, Il and III), such as injectable dermal fillers, post surgical antiadherence materials, devices for healing sores and wounds, etc., in slow-release galenical formulations, etc.).
  • the rheological tests demonstrate that the derivatives according to the invention possess rheological properties characterised by viscoelastic behaviour which can be modulated according to the degree of autocrosslinking of the system, which ranges from a solution to that characteristic of a strong gel. It was found that the viscosity at low shear rates and the resistance to the force applied could be easily modulated. Finally, it was found that the polymer mixtures of the invention have a good ability to recover their viscoelastic properties after a rheological history of imposed stresses (pseudoplastic properties).
  • the invention also relates to the process for the preparation of these derivatives comprising the reaction, in homogenous phase in the protic, polar solvent formamide, of the salt of a monovalent inorganic cation, such as sodium or potassium, of the selected carboxylated polysaccharide with an anhydride of an alkylcarboxylic acid, such as acetic, butyric, isobutyric, valeric, isovaleric or crotonic anhydride, etc., in the presence of a basic catalyst containing an atom of trisubstituted nitrogen, or an inorganic base such sodium or potassium salt of phosphoric acid or a salt of an organic acid with sodium or potassium.
  • a basic catalyst containing an atom of trisubstituted nitrogen, or an inorganic base
  • an inorganic base such sodium or potassium salt of phosphoric acid or a salt of an organic acid with sodium or potassium.
  • the range of the hydroxyl residues involved in ester bonds with the acyl residue deriving from the anhydride is between 0.01 and 0.9xN, where N is the number of hydroxyls in the repetitive unit.
  • the formate ester formed by the formamide hydrolysis in the particular reaction environment may not be higher than 0.2.
  • the starting polysaccharides can be in native form or differently modified according to the chemical functions present.
  • Acid polysaccharides either in acid form or in the form of their inorganic salts, according to the invention are glycosaminoglycan selected from: hyaluronan, chondroitin sulphate, heparan sulphate, dermatan sulphate, keratan sulphate. Hyaluronic acid is particularly preferred.
  • the molecular weight of the polysaccharides according to the invention can vary within a wide range, e.g. between 10 3 and 10 7 Daltons.
  • the products according to the invention can be used as moisturising
  • the products according to the invention can also be advantageously used as a carrier for the controlled release or absorption of active drugs.
  • the 1 H NMR analyses are conducted in D2O with a Bruker Advance 400 spectrometer equipped with a 5 mm multinuclear probe with gradient z, at 300 0 K.
  • the analyses also use diffusion-ordered experiments (DOSY: Diffusion Ordered Spectroscopy).
  • the rheological tests were performed with a Rheostress Haake RS150 controlled-stress rotational rheometer.
  • Example 1 Synthesis of cross-linked hyaluronic acid, sodium salt, acetate ester; degree of autocrosslinking (AUC): 0.07; degree of esterification (DE): 0.19 (acetate), 0.12 (formate)
  • Example 2 Synthesis of cross-linked hyaluronic acid, sodium salt, acetate ester; degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.16 (acetate), 0.01 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 80°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 235 ⁇ L of acetic anhydride (2.49 mmols) and 311 ⁇ L of triethylamine (2.23 mmols) were added. After 16 hours, a further 320 ⁇ L of triethylamine (2.29 mmols) was added, and the system was left to stir for further 6 hours.
  • the gel was then transferred, slowly and under constant agitation, into 70 mL of an 0.2 M solution of NaCI, and neutralised with KHaPO 4 . After approx. 16 hours' agitation, the system was transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, it was frozen and freeze-dried.
  • Example 3 Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.15 (acetate), 0.05 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 235 ⁇ l_ of acetic anhydride (2.49 mmols) and 277 ⁇ l_ of triethylamine (1.99 mmols) were added. After 16 hours' reaction, a further 417 ⁇ l_ of triethylamine (3.00 mmols) was added, and the system was left to stir for another 6 hours.
  • AUC degree of autocrosslinking
  • DE degree of esterification
  • the gel was then transferred, slowly and under constant agitation, into 70 ml_ of an 0.2 M solution of NaCI, and then to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, it was frozen and freeze-dried. 0.98 g of white lyophilisate was obtained.
  • Example 4 Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.12 (acetate), 0.03 (formate)
  • reaction mixture was then transferred into 100 mL of an 0.2 M solution of NaCI, poured into a dialysis membrane (cut-off 12,000 D) and dialysed, firstly against an 0.2 M solution of NaCI and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 1.00 g of white lyophilisate was obtained.
  • Example 5 Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.01; degree of esterification (DE): 0.05 (acetate), 0.01 (formate)
  • reaction mixture was then transferred into 100 mL of demineralised water, poured into a dialysis membrane (cut-off 12000 D) and dialysed, firstly against an 0.2 M solution of NaCI and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.89 g of white lyophilisate was obtained.
  • Example 7 Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.23 (acetate), 0.19 (formate)
  • Example 8 Synthesis of cross-linked hyaluronic acid propionate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.06 (propionate), 0.07 (formate)
  • reaction mixture was then maintained under agitation for approximately 3 hours, and a further 320 ⁇ L of triethylamine (2.30 mmols) was added. After 2 hours, the gel was transferred into 100 mL of demineralised water and neutralised with KH2PO4. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water.
  • Example 9 Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.06; degree of esterification (DE): 0.18 (butyrate), 0.08 (formate)
  • reaction mixture was then maintained under agitation for approximately 20 hours, and a further 550 ⁇ l_ of triethylamine (3.95 mmols) was added. After 6 hours, the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
  • Example 10 Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.15 (butyrate), 0.15 (formate) 1.01 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.52 mmols of monomer units, was dissolved in 33 mL of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 490 ⁇ l_ of butyric anhydride (3.00 mmols) and 280 ⁇ l_ of triethylamine (2.01 mmols) were added.
  • reaction mixture was then maintained under agitation for approximately 5 hours, and a further 280 ⁇ l_ of triethylamine (2.01 mmols) was added. After 16 hours, the gel was transferred into 150 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
  • Example 11 Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.08 (butyrate), 0.02 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 80 0 C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 360 ⁇ l_ of butyric anhydride (2.20 mmols) and 311 ⁇ l_ of triethylamine (2.23 mmols) were added.
  • reaction mixture was then maintained under agitation for approximately 16 hours, and a further 311 ⁇ L of triethylamine (2.23 mmols) was added. After 6 hours 30 minutes the gel was transferred into approx. 40 mL of an 0.2 M solution of NaCI, transferred to a dialysis membrane (cut-off 12000 D), and exhaustively dialysed against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.90 g of white lyophilisate was obtained.
  • Example 12 Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.10 (butyrate), 0.08 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.52 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 244 ⁇ l_ of butyric anhydride (1.49 mmols) and 173 ⁇ l_ of triethylamine (1.24 mmols) were added.
  • reaction mixture was then maintained under agitation for approximately 16 hours, and a further 208 ⁇ l_ of triethylamine (1.49 mmols) was added. After 6 hours, the gel was transferred into 100 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
  • Example 13 Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.02; degree of esterification (DE): 0.06 (butyrate), 0.05 (formate)
  • the gel was transferred into 150 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
  • Example 14 Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.01; degree of esterification (DE): 0.06 (butyrate), 0.02 (formate)
  • reaction mixture was then maintained under agitation for 18 hours, and a further 740 ⁇ l_ of triethylamine (5.32 mmols) was added. After 6 hours, the system was transferred into 200 mL of demineralised water, neutralised with KH2PU4, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against water.
  • Example 15 Synthesis of cross-linked butyrate, acetate and formate ester hyaluronic acid sodium salt; degree of autocrossli ⁇ king (AUC): 0.03; degree of esterification (DE): 0.12 (butyrate), 0.14 (acetate), 0.06 (formate)
  • reaction mixture was then maintained under mechanical stirring for approximately 30 minutes, and 2 ml of a formamide solution containing 1.21 g of potassium acetate (12.3 mmols) were added. After 16 hours, the gel was transferred into 200 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
  • AUC degree of autocrosslinking
  • DE degree of esterification
  • DE degree of esterification
  • MW 439 g/mol, 1.14
  • reaction mixture was then maintained under agitation for 19 hours, and a further 143 ⁇ l_ of triethylamine (1.03 mmols) was added. After A ⁇ A hours the system was transferred into 100 mL of an 0.2 M solution of NaCI, and neutralised with KH2PO4. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.45 g of white lyophilisate was obtained.
  • Example 17 Synthesis of cross-linked hyaluronic acid crotonate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.08 (crotonate), 0.10 (formate)
  • the reaction mixture was maintained under agitation for 18 hours, and a further 320 ⁇ l_ of triethylamine (2.30 mmols) was added. After 7 hours 30 minutes the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against an aqueous solution of 0.2 M NaCI and secondly against ultrapure water.
  • Example 18 Synthesis of cross-linked hyaluronic acid isovalerate (or 3-methyl-butyrate) sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.08 (isovalerate), 0.02 (formate)
  • reaction mixture was maintained under agitation for 16 hours, and a further 167 ⁇ L of triethylamine (1.20 mmols) was added. After 6 hours, the gel was transferred into 100 mL of demineralised water and neutralised with
  • Example 19 Preparation of a syringe containing 1.5 ml of a 2% hydrogel based on autocrosslinked polymer as obtained according to Example 15. 30 mg of the liophylised autocrosslinked polymer, as obtained according to Example 15, were weighted in a 2.0 ml syringe and 1.47g of a water solution containing 0.9% (w/V) sodium chloride were added. All the experimental procedures were conducted under a vertical laminar flow cabinet using pyrogen free materials; the above mentioned physiological solution was prepared using pyrogen free water. The polymer was left to swell for 24 hours at room temperature. Finally the syringe was sterilized by means of a standard thermal cycle ad 121 0 C for 16 minutes. RHEOLOGICAL CHARACTERISATION OF ESTERIFIED AND
  • a magnetic field generates a torque on the upper mobile measurement sensor, air-bearing supported, that converts in stress applied on the sample.
  • the resultant rotational degree and speed of the mobile measurement system are detected by an optical laser system, and thus the strain expended by the sample in response to the shear stress, and the shear rate are estimated.
  • the rheometer used was a Rheostress Haake RS150, equipped with rough or smooth surfaces sensors useful for all types of measurements in rotation and oscillation, respectively for high or low structured systems. All measurements were done at 25°C, using a specific thermocontroller.
  • Figure 1 shows how zero-shear viscosity ranges from 0,01 Pa*s to 100.000 Pa*s by increasing cross-link degree, and how qualitative and quantitative changes occurred on rheological properties over the wide shear stress range.
  • Compounds having a low cross-linking degree behave like solutions while the more crosslinked they are, the more plastic they become. Infact, their profiles range from close to Newtonian to apparently plastic behaviour, characterized by a dramatic viscosity drop of many orders of magnitude over a narrow shear stress range.
  • Figure 2 shows the mechanical spectra of different systems. No mechanical spectra could be recorded for the compounds having the lowest crosslinking degree indicated as reference and example 14, since a linear viscoelasticity field could not be recognised.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Acid polysaccharides characterised by the concomitant presence of partial esters with non-polysaccharide carboxylic acids and esters between the acid groups of the initial polysaccharide and the alcohol groups of the repetitive units, with the formation of crosslinking among the polysaccharide chains. Process for the preparation of these derivatives comprising the reaction, in homogenous phase in the protic, polar solvent formamide, of the salt of a monovalent inorganic cation of the selected carboxylated polysaccharide with an anhydride of an alkylcarboxylic acid in the presence of a basic catalyst containing an atom of trisubstituted nitrogen. The formamide hydrolysis leads to the formation of a formate ester.

Description

DERIVATIVES OF ACiD POLYSACCHARIDES
This invention relates to acid autocrosslinked polysaccharides characterised by the concomitant presence of esters with non-polysaccharide carboxylic acids and esters between the acid groups of the same polysaccharide and the alcoholic groups of the repetitive units. Prior art
In view of their chemico-physical and biological-biochemical characteristics, carboxylated polysaccharides, whether natural or semisynthetic, constitute raw materials of considerable interest for a wide variety of applications in the pharmaceutical and cosmetic industries. Some of them, such as hyaluronic acid (HA), are particularly valued for their high level of biotolerability and hydratability. The choice of material is often connected with cost aspects based on the value and importance of the final application.
Many structural changes have been made to these polysaccharides in recent years to optimise their characteristics and make them as suitable as possible for the desired applications. These changes usually involve the alcohol groups of the repetitive units, the carboxyl groups and, if present, the amino groups.
The prior art as a whole describes two specific structural solutions: 1) simple monoesterification of the alcoholic hydroxyls of the repetitive polysaccharide units, regardless of their nature and origin, with organic acids, without intermolecular crossϋnking;
2) formation of autocrosslinking esters between the hydroxyls of the repetitive polysaccharide units and the carboxyls present in the polysaccharide.
EP 0941253 describes the synthesis of HA derivatives with butyric anhydride in a basic environment, to obtain a product not crosslinked, having esterified hydroxy groups and which does not undergo any significant modification of its viscoelastic properties in aqueous solution. The process involves the use of the quaternary ammonium salt of HA and dimethylformamide (DMF) as aprotic solvent.
In EP 341745, starting from HA or from HA wherein the carboxyls are partially esterified with alcohols of various types, including biologically active alcohols, the carboxyl function of HA (or of its ester derivatives, defined as "external") is involved in the formation of intra- or intermolecular esters with the alcoholic hydroxyls of the repetitive units, with consequent crosslinking (defined as "autocrosslinking") and inducement of viscoelastic characteristics which did not exist in the starting polysaccharide. EP 341745 teaches that autocrosslinking is obtained by "activating" the carboxyl by substituting the -OH group with an electron-attractor group X that allows the carbonyl carbon to be attached by a nucleophil (such as the -OH group of the monosaccharide units), with simultaneous detachment of X. The reagents described which are able to activate the carboxyl are the typical, well-known reagents that supply activated esters in peptide synthesis, such as water-soluble carbodiimides, carbonyldiimidazole, carbonyltriazole, N-hydroxysuccinimide, p-nitrophenol, p-nitrophenyltrifluoracetate, and salts of 2-halogen-N-alkylpyridine [T. Mukaiyama, Ang. Chem., 10 (18) 1979, 707-808]; the reaction is catalysed with triethylamine (TEA). The starting carboxylated polysaccharides are salified as tetrabutylammonium (TBA) salts soluble in aprotic solvents, such as dimethyl sulphoxide (DMSO), to obtain a single reaction phase. The same patent also claims the use of sodium salts in the same aprotic organic solvents to conduct the same reaction. However, this conflicts with the knowledge of the skilled person and with the example given in the patent, as it is well known that this salt is not soluble in solvents such as DMF or DMSO. Since the modulation of the chemico-physical, Theological and biological characteristics (in the broadest sense) of products based on carboxylated polysaccharides is crucial for the purpose of the desired final application(s), and the problem does not appear to have been solved to date, at least in the field of this invention, there is a strongly-felt need for products with adjustable, reproducible, advantageous characteristics, especially their rheological properties in terms of the viscosity of solutions at different concentrations, viscoelasticity and biotolerability. Description of the invention It has now been found that the above-mentioned objectives can be achieved with autocrosslinked polysaccharide derivatives, characterised by the concomitant presence of esters with non-polysaccharide carboxylic acids and esters between the acid groups of the same polysaccharide and the alcoholic groups of their repetitive units. Compounds simultaneously exhibiting the features of esterification to the hydroxyl groups and autocrosslinking have not been disclosed in the prior art.
The invention relates to natural or semisynthetic derivatives of acid polysaccharides wherein the alcoholic groups of the repetitive units occur, more or less extensively, in the form of esters with non-polysaccharide carboxylic acids, and the uronic acid groups are esterified, to a different extent, with other free alcoholic groups present in the polysaccharide chains. This latter type of bond induces autocrosslinking of the polysaccharide, thus influencing the viscoelastic behaviour of the end products; a suitable choice of acyl residue used to esterify the alcoholic hydroxyls enables other chemico-physical properties, such as hydrophilia/lipophilia and viscosity, to be modulated. The degree of autocrosslinking, which is adjustable and reproducible, influences the characteristics of the final products (rigid gels, weak gels, products with increased viscosity). In view of their chemico-physical and rheological characteristics, the derivatives according to the invention can be used as constituents of medical devices of various grades (I, Il and III), such as injectable dermal fillers, post surgical antiadherence materials, devices for healing sores and wounds, etc., in slow-release galenical formulations, etc.).
The rheological tests demonstrate that the derivatives according to the invention possess rheological properties characterised by viscoelastic behaviour which can be modulated according to the degree of autocrosslinking of the system, which ranges from a solution to that characteristic of a strong gel. It was found that the viscosity at low shear rates and the resistance to the force applied could be easily modulated. Finally, it was found that the polymer mixtures of the invention have a good ability to recover their viscoelastic properties after a rheological history of imposed stresses (pseudoplastic properties). The invention also relates to the process for the preparation of these derivatives comprising the reaction, in homogenous phase in the protic, polar solvent formamide, of the salt of a monovalent inorganic cation, such as sodium or potassium, of the selected carboxylated polysaccharide with an anhydride of an alkylcarboxylic acid, such as acetic, butyric, isobutyric, valeric, isovaleric or crotonic anhydride, etc., in the presence of a basic catalyst containing an atom of trisubstituted nitrogen, or an inorganic base such sodium or potassium salt of phosphoric acid or a salt of an organic acid with sodium or potassium. The range of the hydroxyl residues involved in ester bonds with the acyl residue deriving from the anhydride is between 0.01 and 0.9xN, where N is the number of hydroxyls in the repetitive unit. Furthermore, the formate ester formed by the formamide hydrolysis in the particular reaction environment may not be higher than 0.2.
The starting polysaccharides can be in native form or differently modified according to the chemical functions present.
The advantage of direct use of an inorganic cation salt is obvious because, as described below, it eliminates the need for preliminary transformation of the polysaccharide into the salt of an organic base (such as TBA) soluble in aprotic solvents such as DMF, DMSO, N-methylpyrrolidone, etc., a lengthy, expensive operation which involves the risk of depolymerisation.
All the tests confirm the modulability and reproducibility of the process according to the invention. Using said process, it is possible to choose which rheological aspect should be given priority in order to obtain products that present a simple increase in their viscosity in solution (low degree of autocrosslinking and different degree of esterification) or derivatives with variable viscoelastic properties ranging from weak gels to strong gels.
Acid polysaccharides, either in acid form or in the form of their inorganic salts, according to the invention are glycosaminoglycan selected from: hyaluronan, chondroitin sulphate, heparan sulphate, dermatan sulphate, keratan sulphate. Hyaluronic acid is particularly preferred.
The molecular weight of the polysaccharides according to the invention can vary within a wide range, e.g. between 103 and 107 Daltons. The products according to the invention can be used as moisturising
(dermo-)cosmetic agents, medical devices, intra-articular viscosupplementation agents, post surgical anti-adherence filling materials, and materials for covering wounds or sores.
The products according to the invention can also be advantageously used as a carrier for the controlled release or absorption of active drugs.
The following examples illustrate the invention in greater detail.
EXAMPLES
The 1H NMR analyses are conducted in D2O with a Bruker Advance 400 spectrometer equipped with a 5 mm multinuclear probe with gradient z, at 3000K. The analyses also use diffusion-ordered experiments (DOSY: Diffusion Ordered Spectroscopy).
The rheological tests were performed with a Rheostress Haake RS150 controlled-stress rotational rheometer.
The determination of the percentage of ester groups of the polysaccharide alcoholic hydroxyls with the various non-polysaccharide carboxylic acids (DE) and with the polysaccharide carboxyls (AUC) was expressed as the molar ratio between the moles of ester and polysaccharide by means of 1H NMR spectroscopic analysis.
A sample of esterified, cross-linked polysaccharide swollen in formamide containing excess propylamine is left under magnetic stirring at ambient temperature for 16 hours. The polysaccharide is recovered by precipitation in acetone, washed with acetone and dried. The solid is analysed by 1H NMR. The acylation reaction of the amine with carboxyl esters (Michael B. Smith and Jerry March - March's Advanced Organic
Chemistry, 5th ed., Wiley Interscience, page 510) is exploited to determine the esters previously used in the crosslinking; this methodology is selective, because the bland conditions used only involve unstable esters. The esters to the hydroxyls are analysed, again with 1H NMR, exploiting the different resonance of the methyls and methylenes of the acyl residues bonded to the hydroxyls compared with the other polymer signals. These analysis are performed after addition of few microliters of a NaOD solution directly inside the NMR tube containing the swollen gel in D2O thus inducing full hydrolysis of both the crosslink esters and the esters with the non-saccharide acids.
The following examples describe the details of the synthesis of some acid autocrosslinked polysaccharides according to the invention.
Example 1 : Synthesis of cross-linked hyaluronic acid, sodium salt, acetate ester; degree of autocrosslinking (AUC): 0.07; degree of esterification (DE): 0.19 (acetate), 0.12 (formate)
1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical stirring. The solution was then cooled to room temperature, and 352 μl_ of acetic anhydride (3.73 mmols) and 312 μl_ of triethylamine (2.24 mmols) were added. After 16 hours reaction, a further 521 μl_ of triethylamine (3.74 mmols) was added, and the system was left to stir for another 6 hours. The gel was then transferred, slowly and under constant agitation, into
100 ml_ of an 0.2 M solution of NaCI, transferred to a dialysis membrane (cut-off 12,000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, it was frozen and freeze-dried. 0.94 g of white lyophilisate was obtained. The product, analysed in accordance with the method described above, presented AUC: 0.07; DE: 0.19 (acetate), 0.12 (formate).
Example 2: Synthesis of cross-linked hyaluronic acid, sodium salt, acetate ester; degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.16 (acetate), 0.01 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 80°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 235 μL of acetic anhydride (2.49 mmols) and 311 μL of triethylamine (2.23 mmols) were added. After 16 hours, a further 320 μL of triethylamine (2.29 mmols) was added, and the system was left to stir for further 6 hours.
The gel was then transferred, slowly and under constant agitation, into 70 mL of an 0.2 M solution of NaCI, and neutralised with KHaPO4. After approx. 16 hours' agitation, the system was transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, it was frozen and freeze-dried.
0.9 g of white lyophilisate was obtained. The product, analysed in accordance with the method described above, presented AUC: 0.05; DE: 0.16 (acetate), 0.01 (formate).
Example 3: Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.15 (acetate), 0.05 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 235 μl_ of acetic anhydride (2.49 mmols) and 277 μl_ of triethylamine (1.99 mmols) were added. After 16 hours' reaction, a further 417 μl_ of triethylamine (3.00 mmols) was added, and the system was left to stir for another 6 hours.
The gel was then transferred, slowly and under constant agitation, into 70 ml_ of an 0.2 M solution of NaCI, and then to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, it was frozen and freeze-dried. 0.98 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.05; DE: 0.15 (acetate), 0.05 (formate). Example 4: Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.12 (acetate), 0.03 (formate)
1.02 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.54 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 120 μl_ of acetic anhydride (1.27 mmols) and 140 μl_ of triethylamine (1.01 mmols) were added. After 22 hours a further 140 μl_ of triethylamine (1.01 mmols) was added, and the gelatinous mass obtained was left to stir for further 6 hours.
The reaction mixture was then transferred into 100 mL of an 0.2 M solution of NaCI, poured into a dialysis membrane (cut-off 12,000 D) and dialysed, firstly against an 0.2 M solution of NaCI and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 1.00 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.12 (acetate), 0.03 (formate). Example 5: Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.01; degree of esterification (DE): 0.05 (acetate), 0.01 (formate)
1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 mL of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 82 μl_ of acetic anhydride (0.87 mmols) and 87 μl_ of triethylamine (0.63 mmols) were added. After 19 hours a further 348 μl_ of triethylamine (2.52 mmols) was added, and the gelatinous mass obtained was left to stir for further 6 hours.
The reaction mixture was then transferred into 100 mL of demineralised water, poured into a dialysis membrane (cut-off 12000 D) and dialysed, firstly against an 0.2 M solution of NaCI and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.89 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.01 ; DE: 0.05 (acetate), 0.01 (formate). Example 6: Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.08 (acetate), 0.18 (formate)
2.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 4.99 mmols of monomer units, was solubilised in 67 ml_ of formamide at 80°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 710 μl_ of acetic anhydride (7.52 mmols) and 970 μl_ of triethylamine (6.97 mmols) were added.
After 2 hours 30 minutes the gel was transferred into 350 ml_ of an 0.2 M solution of NaCI, and the mixture was transferred to a dialysis membrane
(cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and then exhaustively against demineralised water. Finally, the sample was frozen and freeze-dried, and 2.1O g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.08. (acetate), 0.18 (formate).
Example 7: Synthesis of cross-linked hyaluronic acid acetate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.23 (acetate), 0.19 (formate)
1.01 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 240 μL of acetic anhydride (2.54 mmols) and a solution of 0.28 g of dimethylaminopyridine (2.29 mmols), dissolved in 2 mL of formamide, were added. After 19 hours, a further 0.56 μl_ of dimethylaminopyridine (4.58 mmols), dissolved in 4 mL of formamide, was added, and the system was stirred for further 5 hours. The gel was then transferred, slowly and under constant agitation, into
150 mL of an 0.2 M solution of NaCI, and neutralised with KH2PO4. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, it was frozen and freeze-dried. 1.09 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.23 (acetate), 0.19 (formate).
Example 8: Synthesis of cross-linked hyaluronic acid propionate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.06 (propionate), 0.07 (formate)
1.02 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.54 mmols of monomer units, was dissolved in 33 mL of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 330 μL of propionic anhydride (2.57 mmols) and 320 μL of triethylamine (2.30 mmols) were added.
The reaction mixture was then maintained under agitation for approximately 3 hours, and a further 320 μL of triethylamine (2.30 mmols) was added. After 2 hours, the gel was transferred into 100 mL of demineralised water and neutralised with KH2PO4. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water.
Finally, the sample was frozen and freeze-dried, and 0.96 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.05; DE: 0.06 (propionate), 0.07 (formate).
Example 9: Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.06; degree of esterification (DE): 0.18 (butyrate), 0.08 (formate)
1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.52 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 610 μl_ of butyric anhydride (3.73 mmols) and 310 μl_ of triethylamine (2.23 mmols) were added.
The reaction mixture was then maintained under agitation for approximately 20 hours, and a further 550 μl_ of triethylamine (3.95 mmols) was added. After 6 hours, the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
Finally, the sample was frozen and freeze-dried, and 0.95 g of white lyophilisate was obtained. The product, analysed in accordance with the method described above, presented AUC: 0.06; DE: 0.18 (butyrate), 0.08 (formate).
Example 10: Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.15 (butyrate), 0.15 (formate) 1.01 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.52 mmols of monomer units, was dissolved in 33 mL of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 490 μl_ of butyric anhydride (3.00 mmols) and 280 μl_ of triethylamine (2.01 mmols) were added.
The reaction mixture was then maintained under agitation for approximately 5 hours, and a further 280 μl_ of triethylamine (2.01 mmols) was added. After 16 hours, the gel was transferred into 150 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
Finally, the sample was frozen and freeze-dried, and 1.00 g of white lyophilisate was obtained. The product, analysed in accordance with the method described above, presented AUC: 0.05; DE: 0.15 (butyrate), 0.15 (formate).
Example 11 : Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.08 (butyrate), 0.02 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 800C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 360 μl_ of butyric anhydride (2.20 mmols) and 311 μl_ of triethylamine (2.23 mmols) were added.
The reaction mixture was then maintained under agitation for approximately 16 hours, and a further 311 μL of triethylamine (2.23 mmols) was added. After 6 hours 30 minutes the gel was transferred into approx. 40 mL of an 0.2 M solution of NaCI, transferred to a dialysis membrane (cut-off 12000 D), and exhaustively dialysed against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.90 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.08 (butyrate), 0.02 (formate).
Example 12: Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.10 (butyrate), 0.08 (formate) 1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.52 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 244 μl_ of butyric anhydride (1.49 mmols) and 173 μl_ of triethylamine (1.24 mmols) were added.
The reaction mixture was then maintained under agitation for approximately 16 hours, and a further 208 μl_ of triethylamine (1.49 mmols) was added. After 6 hours, the gel was transferred into 100 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
Finally, the sample was frozen and freeze-dried, and 0.95 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.1 (butyrate), 0.08 (formate). Example 13: Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.02; degree of esterification (DE): 0.06 (butyrate), 0.05 (formate)
1.00 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.49 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical stirring. The solution was then cooled to ambient temperature, and 210 μl_ of butyric anhydride (1.28 mmols) and 140 μl_ of triethylamine (1.0 mmols) were added. The reaction mixture was then maintained under agitation for 17 hours, and a further 320 μl_ of triethylamine (3.00 mmols) was added. After 6 hours
30 minutes the gel was transferred into 150 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
Finally, the sample was frozen and freeze-dried, and 0.99 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.02; DE: 0.06 0.06 (butyrate), 0.05 (formate). Example 14: Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.01; degree of esterification (DE): 0.06 (butyrate), 0.02 (formate)
1.01 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.52 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 125 μl_ of butyric anhydride (0.76 mmols) and 75 μl_ of triethylamine (0.5 mmols) were added.
The reaction mixture was then maintained under agitation for 18 hours, and a further 740 μl_ of triethylamine (5.32 mmols) was added. After 6 hours, the system was transferred into 200 mL of demineralised water, neutralised with KH2PU4, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against water.
Finally, the sample was frozen and freeze-dried, and 0.82 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.01 ; DE: 0.06 (butyrate), 0.02 (formate).
Example 15: Synthesis of cross-linked butyrate, acetate and formate ester hyaluronic acid sodium salt; degree of autocrossliπking (AUC): 0.03; degree of esterification (DE): 0.12 (butyrate), 0.14 (acetate), 0.06 (formate)
1.65 g of hyaluronic acid in the form of sodium salt, injection grade, with a molecular weight of approx. 500 kD, equal to 4.11 mmols of monomer units, was dissolved in 33 ml_ of formamide at 95°C, under nitrogen flow, with mechanical stirring. The solution was then cooled to room temperature and
670 μl_ of butyric anhydride (4.1 mmols) were added.
The reaction mixture was then maintained under mechanical stirring for approximately 30 minutes, and 2 ml of a formamide solution containing 1.21 g of potassium acetate (12.3 mmols) were added. After 16 hours, the gel was transferred into 200 ml_ of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against ultrapure water.
All the reaction and purification equipment was confined under a vertical laminar flow cabinet to prevent contamination. The glassware and the water were pyrogen free.
Finally, the sample was frozen and freeze-dried, and 1.60 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.12 (butyrate), 0.14 (acetate), 0.06 (formate).
Example 16: Synthesis of cross-linked hyaluronic acid butyrate sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.55 (butyrate), 0.15 (formate) 0.50 g of hyaluronic acid butyrate in the form of sodium salt (degree of butyration, namely moles of butyric groups on moles of polysaccharide, equal to approx. 0.54, MW=439 g/mol, 1.14 mmols) was dissolved in 17 ml_ of formamide at 600C, under nitrogen flow and with mechanical agitation. The solution was then cooled to ambient temperature, and 186 μl_ of butyric anhydride (1.14 mmols) and 143 μl_ of triethylamine (1.03 mmols) were added.
The reaction mixture was then maintained under agitation for 19 hours, and a further 143 μl_ of triethylamine (1.03 mmols) was added. After AΛA hours the system was transferred into 100 mL of an 0.2 M solution of NaCI, and neutralised with KH2PO4. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against 0.2 M NaCI and secondly against demineralised water. Finally, the sample was frozen and freeze-dried, and 0.45 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.55 (butyrate), 0.15 (formate).
Example 17: Synthesis of cross-linked hyaluronic acid crotonate sodium salt, degree of autocrosslinking (AUC): 0.05; degree of esterification (DE): 0.08 (crotonate), 0.10 (formate)
1.02 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 2.54 mmols of monomer units, was dissolved in 32 mL of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 380 μl_ of crotonic anhydride (2.56 mmols) and 320 μl_ of triethylamine (2.30 mmols) were added.
The reaction mixture was maintained under agitation for 18 hours, and a further 320 μl_ of triethylamine (2.30 mmols) was added. After 7 hours 30 minutes the gel was transferred into 150 mL of ultrapure water, transferred to a dialysis membrane (cut-off 12000 D) and dialysed, firstly against an aqueous solution of 0.2 M NaCI and secondly against ultrapure water.
Finally, the sample was frozen and recovered by freeze-drying. 0.45 g of white lyophilisate was obtained.
The product, analysed in accordance with the method described above, presented AUC: 0.05; DE: 0.08 (crotonate), 0.10 (formate).
Example 18: Synthesis of cross-linked hyaluronic acid isovalerate (or 3-methyl-butyrate) sodium salt, degree of autocrosslinking (AUC): 0.03; degree of esterification (DE): 0.08 (isovalerate), 0.02 (formate)
0.48 g of hyaluronic acid in the form of sodium salt, with a molecular weight of approx. 300 kD, equal to 1.21 mmols of monomer units, was dissolved in 16 mL of formamide at 95°C, under nitrogen flow, with mechanical agitation. The solution was then cooled to ambient temperature, and 240 μl_ of isovaleric anhydride (1.20 mmols) and 150 μl_ of triethylamine (1.08 mmols) were added.
The reaction mixture was maintained under agitation for 16 hours, and a further 167 μL of triethylamine (1.20 mmols) was added. After 6 hours, the gel was transferred into 100 mL of demineralised water and neutralised with
KH2PO4, and 2.5 g of NaCI was added. It was then transferred to a dialysis membrane (cut-off 12000 D) and dialysed against water.
Finally, the sample was frozen and recovered by freeze-drying.
0.89 g of white lyophilisate was obtained. The product, analysed in accordance with the method described above, presented AUC: 0.03; DE: 0.08 (isovalerate), 0.02 (formate).
Example 19: Preparation of a syringe containing 1.5 ml of a 2% hydrogel based on autocrosslinked polymer as obtained according to Example 15. 30 mg of the liophylised autocrosslinked polymer, as obtained according to Example 15, were weighted in a 2.0 ml syringe and 1.47g of a water solution containing 0.9% (w/V) sodium chloride were added. All the experimental procedures were conducted under a vertical laminar flow cabinet using pyrogen free materials; the above mentioned physiological solution was prepared using pyrogen free water. The polymer was left to swell for 24 hours at room temperature. Finally the syringe was sterilized by means of a standard thermal cycle ad 1210C for 16 minutes. RHEOLOGICAL CHARACTERISATION OF ESTERIFIED AND
CROSS-LINKED DERIVATIVES
Rheological studies highlight how polymeric systems examined exhibit a wide variety of rheological behaviours depending on the cross-linking density of the network. Indeed for different system reticulation degree, low shear viscosity differs of many decades, and flow curves dramatically vary from a viscous liquid to an elastic solid profile. Further viscoelastic behaviour ranges from solution-like to strong-gel-like confirming the properties variability of products object of the present invention.
Method and results For rheological measurements we used a controlled stress rheometer, a mechanical spectrometer capable of subjecting a sample to either a dynamic (sinusoidal) or steady (linear) shear stress.
A magnetic field generates a torque on the upper mobile measurement sensor, air-bearing supported, that converts in stress applied on the sample. At the same time, the resultant rotational degree and speed of the mobile measurement system are detected by an optical laser system, and thus the strain expended by the sample in response to the shear stress, and the shear rate are estimated.
The rheometer used was a Rheostress Haake RS150, equipped with rough or smooth surfaces sensors useful for all types of measurements in rotation and oscillation, respectively for high or low structured systems. All measurements were done at 25°C, using a specific thermocontroller.
Three types of measurements were done in order to characterize the products according to the invention:
- flow curves: continuous/steady state measurements of viscosity over a wide range of shear rate or shear stress;
- stress and frequency sweep: dynamic measurements (oscillation) for the determination of samples viscoelastic behaviour. In particular stress sweep is done in order to individuate the linear viscoelastic range extension, and thus the critical strain value for the linear/non linear transition. Frequency sweep gives systems' mechanical spectra, that are the storage modulus G' and the loss modulus G" profiles over a wide range of frequency, in the linear viscoelasticity field.
- recovery sweep: to evaluate the viscoelastic properties recovery of a sample undergone a certain rheological history: three measurement cycles are applied, each one composed by oscillatory steps, under constant amplitude and frequency of strain, before and after the application of a constant shear rate (respectively 100s-1, 100s-1, 500s-1 during each cycle)
The tests were conducted on samples swollen in saline at the concentration of 1 % w/w. Examples of flow curves and mechanical spectra, in figure 2, of a hyaluronan butyrate esters family in physiological solution 1 % w/w, with different cross-linking degree, prepared as described in examples 10, 13, 14 and of the reference standard (HA sodium salt, Mw = 30OkDa) are shown in Figures 1 and 2, respectively. Flow curves - continuous steady state tests
Figure 1 shows how zero-shear viscosity ranges from 0,01 Pa*s to 100.000 Pa*s by increasing cross-link degree, and how qualitative and quantitative changes occurred on rheological properties over the wide shear stress range. Compounds having a low cross-linking degree behave like solutions while the more crosslinked they are, the more plastic they become. Infact, their profiles range from close to Newtonian to apparently plastic behaviour, characterized by a dramatic viscosity drop of many orders of magnitude over a narrow shear stress range.
Oscillatory tests
Figure 2 shows the mechanical spectra of different systems. No mechanical spectra could be recorded for the compounds having the lowest crosslinking degree indicated as reference and example 14, since a linear viscoelasticity field could not be recognised.
As to the other two compounds, it is possible to observe the transition from a solution behaviour to a strong gel profile. Solutions show a viscous modulus (G") higher than the elastic one (G') at low frequencies, while, as the frequency are increased, a module cross-over that takes. Strong gels show a storage modulus higher than the viscous one over the whole experimental range of frequencies. The more structured the systems are, the higher the module values are.
Recovery tests
The behaviour of compounds described in example 13 is shown during a recovery test in figures 3a, 3b, 3c: it is possible to observe a complete recovery of both elastic and viscous components in each step.
Conclusions
These studies proved that some representative derivatives according to the invention, submitted to rheological characterization, exhibit different viscoelastic behaviours depending on cross-linking degree, ranging from a viscous solution to a strong gel-like behaviour. Furthermore, it was demonstrated the high capacity in recovering viscoelastic properties after a complete rheological working schedule applied. All experimental results confirm the great flexibility and reproducibility of the process of the invention for the synthesis of the claimed compounds.
The results of the rheological characterisation of some samples representative of the products obtained are set out in Table 1.
Figure imgf000023_0001
(1) The gel was swollen in a 0.9% NaCI at pH=5.5 water solution; the polymer concentration was 2% w/w.

Claims

1. Acid autocrosslinked polysaccharides characterised by the concomitant presence of esters with non-polysaccharide carboxylic acids and esters between the acid groups of the same polysaccharide and the alcoholic groups of the repetitive units.
2. Acid autocrosslinked polysaccharides as claimed in claim 1 , comprising repetitive units containing at least one uronic acid residue.
3. Acid autocrosslinked polysaccharides as claimed in claim 2, wherein the starting polysaccharide is a glicosaminoglycan selected from hyaluronan, chondroitin sulphate, heparan sulphate, dermatan sulphate, keratan sulphate.
4. Acid autocrosslinked polysaccharides as claimed in any of claims 1 to 3, wherein the carboxyl functions are present in acid or salified form. 5. Acid autocrosslinked polysaccharides as claimed in claim 4, wherein the carboxyl functions are salified with alkaline metals, in particular sodium. 6. Acid autocrosslinked polysaccharides as claimed in any of claims 1 to
5. characterised by a molecular weight selected between 103 and 107 Daltons. 7. Acid autocrosslinked polysaccharides as claimed in any of claims 1 to
6. in which the non polysaccharide carboxylic acid is chosen in the group of acetic, propionic, butyric, isobutyric, valeric, isovaleric and crotonic (group A) and formic.
8. Acid autocrosslinked polysaccharides as claimed in any of claims 1 to 6, wherein the esters of acids of group A on the hydroxyls present a degree of substitution ranging between 0.01 and 0.9xN, where N is the number of hydroxyls present in the repetitive unit, whereas the formic ester is present in the range between 0 and 0.2.
9. Acid autocrosslinked polysaccharides as claimed in claim 8, wherein the esters of the group A on the hydroxyls present a degree of substitution ranging between 0.01 and 0.5 in relation to the repetitive unit.
10. Process for the preparation of the acid autocrosslinked polysaccharides of claims 1-9, which comprises the following steps: a) heating solubilisation of the carboxylated polysaccharide in formamide; b) addition of an anhydride of the non-polysaccharide acid at room temperature for a time comprised between 10 minutes and 2 hours; c) addition of the base and allow to react at room temperature for a period between 4 hours and 24 hours; d) addition of a water solution of sodium chloride and neutralisation to a pH between 6 and 7.5; e) purification of the reaction mixture by means of dialyses ; f) recovery of the polymer by means of lyophilization.
11. Process as claimed in claim 10, wherein the anhydride is the anhydride chosen from the acetic, propionic, butyric, isobutyric, valeric, isovaleric and crotonic.
12. Process as claimed in any of claims 10 to 11 , wherein the base is chosen among an organic base containing an atom of trisubstituted nitrogen, an inorganic base preferably sodium or potassium salt of phosphoric acid, a salt of an organic acid with sodium and potassium, preferably potassium and sodium acetate.
13. Process for the preparation of the acid autocrosslinked polysaccharides as described in claim 10, wherein the formate ester is formed from the hydrolysis of formamide in the presence of one of the anhydrides as described in claim 11 and one of the bases as described in claim 12.
14. Use of acid polysaccharides of claims 1-9 as medical devices, moisturising agents, intra-articular viscosupplementation agents, anti-tissue adherence filling materials in surgery and materials for covering wounds and sores.
PCT/IB2007/003973 2006-12-29 2007-12-18 Derivatives of acid polysaccharides WO2008081255A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2009543534A JP5372773B2 (en) 2006-12-29 2007-12-18 Derivatives of acidic polysaccharides
CA2673947A CA2673947C (en) 2006-12-29 2007-12-18 Derivatives of acid polysaccharides
EP07859095.7A EP2097457B1 (en) 2006-12-29 2007-12-18 Derivatives of acid polysaccharides
PL07859095T PL2097457T3 (en) 2006-12-29 2007-12-18 Derivatives of acid polysaccharides
AU2007341078A AU2007341078B2 (en) 2006-12-29 2007-12-18 Derivatives of acid polysaccharides
ES07859095.7T ES2633712T3 (en) 2006-12-29 2007-12-18 Acid polysaccharide derivatives
US12/521,307 US8247546B2 (en) 2006-12-29 2007-12-18 Derivatives of acid polysaccharides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06425874.2 2006-12-29
EP06425874A EP1942117A1 (en) 2006-12-29 2006-12-29 Derivatives of acid polysaccharides

Publications (1)

Publication Number Publication Date
WO2008081255A1 true WO2008081255A1 (en) 2008-07-10

Family

ID=37904391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003973 WO2008081255A1 (en) 2006-12-29 2007-12-18 Derivatives of acid polysaccharides

Country Status (9)

Country Link
US (1) US8247546B2 (en)
EP (2) EP1942117A1 (en)
JP (1) JP5372773B2 (en)
AU (1) AU2007341078B2 (en)
CA (1) CA2673947C (en)
ES (1) ES2633712T3 (en)
PL (1) PL2097457T3 (en)
PT (1) PT2097457T (en)
WO (1) WO2008081255A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068215A1 (en) * 2007-11-27 2009-06-04 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
EP2522337A2 (en) 2011-05-13 2012-11-14 Rottapharm S.P.A. Hyaluronic acid esters, their preparation and use in dermatology
IT201900021693A1 (en) 2019-11-20 2021-05-20 Bmg Pharma S P A BUTYRATED OR BUTYRATED DERIVATIVES AND FORMS OF CROSS-LINKED HYALURONIC ACID AND THEIR CROSS-LINKING PROCEDURE

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101078302B1 (en) * 2008-05-29 2011-10-31 (주)프로넥스 Drug Delivery System
FR2983483B1 (en) * 2011-12-02 2014-11-14 Vivacy Lab PROCESS FOR SIMULTANEOUS SUBSTITUTION AND RETICULATION OF A POLYSACCHARIDE VIA ITS HYDROXYL FUNCTIONS
CZ2012842A3 (en) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. C6-C18-acylated hyaluronate-based nanomicellar composition, process for preparing C6-C18-acylated hyaluronate, process for preparing nanomicellar composition and stabilized nanomicellar composition as well as use thereof
CZ304977B6 (en) 2013-11-21 2015-02-25 Contipro Biotech S.R.O. Nanofibers comprising photocurable ester derivative of hyaluronic acid or a salt thereof, photocured nanofibers, method of their synthesis, composition comprising photocured nanofibers and use thereof
CZ2014150A3 (en) 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Conjugates of hyaluronic acid oligomer or salts thereof, process of their preparation and use
CZ2014451A3 (en) 2014-06-30 2016-01-13 Contipro Pharma A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, process of its preparation and use
DK3245233T3 (en) * 2015-01-13 2019-01-28 Bmg Pharma S P A PROCEDURE IN WATER FOR THE PREPARATION OF HYBRID ACID ESTERS OF HYALURONIC ACID SODIUM SALT
CZ309295B6 (en) 2015-03-09 2022-08-10 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of its preparation and use
CZ306479B6 (en) 2015-06-15 2017-02-08 Contipro A.S. A method of crosslinking polysaccharides by using photolabile protecting groups
CZ306662B6 (en) 2015-06-26 2017-04-26 Contipro A.S. Sulphated polysaccharides derivatives, the method of their preparation, the method of their modification and the use
CZ308106B6 (en) 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN110732037B (en) 2018-07-20 2023-05-26 广州倍绣生物技术有限公司 Hemostatic paste and preparation method thereof
CN110467691A (en) * 2019-09-23 2019-11-19 山东银河生物科技有限公司 A method of preparing acetylation hyaluronic acid
CN110981991B (en) * 2019-12-24 2021-12-07 江苏诚信药业有限公司 Preparation method of acetylated hyaluronate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589226A (en) * 1946-11-22 1952-03-18 Us Agriculture Acylation of polysaccharides in formamide
US4152170A (en) * 1975-06-18 1979-05-01 Sumitomo Chemical Company, Ltd. Cross-linked pullulan
FR2752843A1 (en) * 1996-08-30 1998-03-06 Sod Conseils Rech Applic CROSS-LINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION SUPPORT
US6410044B1 (en) * 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758577A (en) * 1971-11-01 1973-09-11 Goodrich Co B F Stabilization of dimethylformamide
JPS51149883A (en) * 1975-06-19 1976-12-23 Sumitomo Chem Co Ltd Hydrophilic gel
EP0091159B1 (en) * 1982-04-02 1985-09-11 Unilever N.V. Process for preparing sugar acetates
IT1198449B (en) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
US5221739A (en) * 1992-01-09 1993-06-22 Eli Lilly And Company Acetylation of 3-hydroxymethyl cephalosporins
IT1286510B1 (en) * 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po BUTYRIC ESTERS WITH ANTI-PROLIFERATIVE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US6007833A (en) * 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
IT1306643B1 (en) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl PROCESS FOR THE PREPARATION OF SELF-CROSS-LINKED COMPOUNDS OF Hyaluronic Acid and ITS DERIVATIVES OBTAINABLE BY TECHNIQUE
ITMI20040605A1 (en) * 2004-03-29 2004-06-29 Coimex S C R L United Companie BUTYRICAL ESTERS OF HYALURONIC ACID WITH LOW DEGREE OF SUBSTITUTION PROCEDURE FOR THEIR PREPARATION AND USE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589226A (en) * 1946-11-22 1952-03-18 Us Agriculture Acylation of polysaccharides in formamide
US4152170A (en) * 1975-06-18 1979-05-01 Sumitomo Chemical Company, Ltd. Cross-linked pullulan
FR2752843A1 (en) * 1996-08-30 1998-03-06 Sod Conseils Rech Applic CROSS-LINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION SUPPORT
US6410044B1 (en) * 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068215A1 (en) * 2007-11-27 2009-06-04 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
US8530450B2 (en) 2007-11-27 2013-09-10 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
EP2522337A2 (en) 2011-05-13 2012-11-14 Rottapharm S.P.A. Hyaluronic acid esters, their preparation and use in dermatology
ITTO20110428A1 (en) * 2011-05-13 2012-11-14 Rottapharm Spa ESTERS OF HYALURONIC ACID, THEIR PREPARATION AND USE IN DERMATOLOGY
EP2522337A3 (en) * 2011-05-13 2013-03-20 Rottapharm S.P.A. Hyaluronic acid esters, their preparation and use in dermatology
US9062129B2 (en) 2011-05-13 2015-06-23 Rottapharm S.P.A. Hyaluronic acid esters, their preparation and use in dermatology
RU2598552C2 (en) * 2011-05-13 2016-09-27 Роттафарм С.П.А. Complex hyaluronic acid esters, their production and use thereof in dermatology
IT201900021693A1 (en) 2019-11-20 2021-05-20 Bmg Pharma S P A BUTYRATED OR BUTYRATED DERIVATIVES AND FORMS OF CROSS-LINKED HYALURONIC ACID AND THEIR CROSS-LINKING PROCEDURE

Also Published As

Publication number Publication date
AU2007341078B2 (en) 2013-03-07
EP1942117A1 (en) 2008-07-09
CA2673947A1 (en) 2008-07-10
AU2007341078A1 (en) 2008-07-10
ES2633712T3 (en) 2017-09-25
CA2673947C (en) 2016-02-23
US20100292459A1 (en) 2010-11-18
US8247546B2 (en) 2012-08-21
EP2097457B1 (en) 2017-07-12
JP5372773B2 (en) 2013-12-18
PL2097457T3 (en) 2017-12-29
EP2097457A1 (en) 2009-09-09
JP2010514878A (en) 2010-05-06
PT2097457T (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CA2673947C (en) Derivatives of acid polysaccharides
JP5661470B2 (en) Polysaccharide derivatives of lipoic acid, their preparation, use as cosmetics for skin and medical devices
Gómez-Mascaraque et al. Oxidized dextrins as alternative crosslinking agents for polysaccharides: application to hydrogels of agarose–chitosan
Liu et al. Synthesis of carboxymethyl chitin in aqueous solution and its thermo-and pH-sensitive behaviors
RU2230073C2 (en) Method for cross-linking carboxylated polysaccharides
US20070053987A1 (en) Cross-linked polysacharide and protein matrices and methods for their preparation
JP5372774B2 (en) Polysaccharide derivatives containing citric acid
CN108264581A (en) A kind of self-crosslinking Sodium Hyaluronate and preparation method thereof
JP2003252905A (en) Crosslinked hyaluronic acid
Putri et al. Rheological and Self-Healing Behavior of Hydrogels Synthesized from L-Lysine-Functionalized Alginate Dialdehyde. Polymers 2023, 15, 1010
WO2021099977A1 (en) Crosslinked butyrate or butyrate-formate derivatives of hyaluronic acid and the crosslinking process thereof
Ying et al. Relationships between the molecular structure and moisture-absorption and moisture-retention abilities of succinyl chitosan
ITTS20010016A1 (en) REGULAR CROSS-LINKED POLYSACCHARIDES.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859095

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REEP Request for entry into the european phase

Ref document number: 2007859095

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007859095

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009543534

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2673947

Country of ref document: CA

Ref document number: 2007341078

Country of ref document: AU

Ref document number: 12521307

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007341078

Country of ref document: AU

Date of ref document: 20071218

Kind code of ref document: A